F. Hoffmann-La Roche Ltd., Merck & Co., Inc. and Bristol-Myers Squibb Company are dominating the Global Lung Cancer Therapeutics Market in 2018

Global Lung Cancer Therapeutics Market is expected to grow at a healthy CAGR of 12.4% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.

Access Full Report at https://databridgemarketresearch.com/reports/global-lung-cancer-therapeutics-market/

The lung cancer therapeutics market is a highly concentrated market which includes key players and local players. The market has witnessed increased various strategic developments owing to favourable market scenario. The market has a prominent growth in upcoming years due to increasing rate of pollution, rising prevalence of lung cancer cases, increasing geriatric population. The initiatives taken by the government to create awareness and healthcare programs initiated by the government which offers healthcare benefits is also posing as an opportunity for the market.

The market has witness developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of innovative technology. For instance, In April 2019, Sun Pharmaceutical Industries has launched INFUGEM injection in the US market. This is used in the treatment of used for treatment of cancer, such as breast, ovarian, non-small cell lung cancers. As this product gives a comprehensive solution for the many types of cancer, so this product launch will give the company the opportunity to grasp more customers.

F. Hoffmann-La Roche Ltd. dominated the global lung cancer therapeutics market. The other key players existing in the market includes Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., Novartis AG, Eli Lilly and Company., AstraZeneca, Boehringer Ingelheim International GmbH, CELGENE CORPORATION, AMGEN INC., Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., ALLERGAN, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd. and others.

F. Hoffmann-La Roche Ltd.:

F. Hoffmann-La Roche Ltd. headquartered in Grenzacherstrasse, Switzerland was founded in 1896. The company focuses on the development, sales and manufacture pharmaceuticals and diagnostics. The company has three operating divisions namely, Pharmaceutical, Medical Devices, Consumer. The pharmaceuticals business division is engaged in R&D and manufacturing of medicines.

  • In March 2019, FDA approved the Roche’s Tecentriq in combination with the chemotherapy for initially treating adults with an extensive stage of small cell lung cancer. This would help company to enhance its customer base.

The company has wide geographic presence in Europe, North America, Asia, Africa, Australia and Oceania. The company has various subsidiaries such as Genentech, Inc. (U.S), Roche Diagnostics Limited (U.K), Chugai Pharmaceutical Co. (Japan), Flatiron Health, Inc. (U.S), Ventana Medical Systems (U.S), Kapa Biosystems, Inc. and others.

Merck & Co., Inc.:

Merck & Co., Inc. headquartered in New York, U.S. was founded in 1891. The company is focused in R&D, manufacturing and marketing products for healthcare industry. The company is a global health care company which delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The company operates its business through three business segments: pharmaceutical, animal health and others. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, which are generally sold by prescription, to treat the human disorders. The company sells the human health pharmaceutical products by drug wholesalers and retailers, government agencies, hospitals, and managed health care providers which include health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products include preventive paediatric, adolescent and adult vaccines, primarily administered at physician offices.

  • In February 2019, GSK and Merck KGaA, Darmstadt, Germany has developed M7824. This is a novel immunotherapy which has potential in treating multiple difficult-to-treat cancer such as non-small cell lung and biliary tract cancers. This increases the company’s product line for this market

The company has wide geographic presence in North America, Latin America, Middle East & Africa, Europe and Asia-Pacific. It operates through its subsidiaries such as Organon International (Netherlands), MSD & Co. (U.S.), Merck Sharp & Dohme ltd. (UK), Johnson & Johnson- Merck Consumer Pharmaceuticals Company (U.S.), Intervet International B.V. (Netherlands) among others.

Bristol-Myers Squibb Company:

Bristol-Myers Squibb Company is headquartered in New York, U.S., established in 1845. The company is focused in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines which helps the patients prevail over serious diseases. The company operates its business through only one business segment: Biopharmaceuticals.

  • In January 2019, Bristol-Myers Squibb is entered into an agreement to acquire Celgene (U.S.). With this acquisition Bristol-Myers Squibb is able to create a premier innovative biopharma company which will increase the company’s product line for the lung cancer therapeutics market.

The company has wide geographic presence in more than 60 countries globally. It operates through its subsidiaries such as Bristol-Myers Squibb GmbH & Co. KGaA (Germany), Adnexus Therapeutics, Inc. (U.S.), Bristol-Myers Squibb S.L. (Spain), Bristol-Myers Squibb A.E. (Greece), Amira Pharmaceuticals, Inc. (U.S.) and others.